Special Issue "New Advances in Female Pelvic Floor Dysfunctions Management"

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Obstetrics and Gynecology".

Deadline for manuscript submissions: 8 April 2022.

Special Issue Editor

Dr. Andrea Braga
E-Mail Website
Guest Editor
PD. Dr. med. of Department of Obstetrics and Gynecology, Ente Ospedaliere Cantonale, University of the Italian Switzerland, Mendrisio, Switzerland
Interests: urogynecology; urinary incontinence; pelvic reconstructive surgery; female urology

Special Issue Information

Dear Colleagues,

Female pelvic floor dysfunctions (PFDs) are common conditions affecting over 20% of the adult population. These disorders, which include urinary incontinence, anal incontinence, pelvic organ prolapse and sexual dysfunction, represent serious health problems for the female population. In fact, in addition to physical discomfort, they could lead to psychological distress, such as anxiety and low self-esteem, until depression status.

The prevalence of PFDs increases with age and it is estimated that the number of American women with at least one pelvic floor disorder will increase from 28.1 million in 2010 to 43.8 million in 2050. Considering the general aging of the global population, these problems could further increase. Besides, due to the embarrassment of patients, the belief that PFDs are a normal and inevitable part of aging and the lack of knowledge about treatment options, the prevalence is often underreported. Less than 20% of symptomatic women self-report their problems.

Furthermore, PFDs have a great impact on financial policy. In the USA, pelvic organ prolapse is thought to be the leading cause of more than 300,000 surgical procedures per year with 25% undergoing reoperations, for a total annual cost of more than 1 billion dollars. Meanwhile, the annual direct cost of urinary incontinence in the USA alone is USD 16.3 billion, of which 3/4 is for the management of women who have this condition.

As women continue to live longer lives, understanding how to promote dialogues between clinicians and patients around these issues and finding therapies to reduce its effect on women’s quality of life, should be a priority for future research. Moreover, it is important to develop the concept of a multidisciplinary approach to PFDs, that in recent years, has led to the improvement of the condition for women.

In this Special Issue, we would like to provide a collection of papers, original articles or clinical/systematic reviews, aimed at providing a comprehensive overview of the recent advances on the diagnosis and treatment of PFDs.

Dr. Andrea Braga
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • female pelvic floor dysfunctions
  • urinary incontinence
  • anal incontinence
  • pelvic organ prolapse
  • sexual dysfunction

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Low Intensity Extracorporeal Shock Wave Therapy as a Novel Treatment for Stress Urinary Incontinence: A Randomized-Controlled Clinical Study
Medicina 2021, 57(9), 947; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57090947 - 08 Sep 2021
Viewed by 587
Abstract
Background and Objectives: To evaluate the effects of low intensity extracorporeal shock wave therapy (LiESWT) on stress urinary incontinence (SUI). Materials and Methods: This investigation was a multicenter, single-blind, randomized-controlled trial study. Sixty female SUI patients were randomly assigned to receive [...] Read more.
Background and Objectives: To evaluate the effects of low intensity extracorporeal shock wave therapy (LiESWT) on stress urinary incontinence (SUI). Materials and Methods: This investigation was a multicenter, single-blind, randomized-controlled trial study. Sixty female SUI patients were randomly assigned to receive LiESWT with 0.25 mJ/mm2 intensity, 3000 pulses, and 3 pulses/s, once weekly for a 4-week (W4) and 8-week (W8) period, or an identical sham LiESWT treatment without energy transmission. The primary endpoint was the changes in urine leakage as measured by a pad test and validated standardized questionnaires, while the secondary endpoint was the changes in a 3-day urinary diary among the baseline (W0), the W4 and W8 of LiESWT, and 1-month (F1), 3-month (F3), and 6-month (F6) follow-up after LiESWT. Results: The results showed that 4 weeks of LiESWT could significantly decrease urine leakage based on the pad test and validated standardized questionnaire scores, as compared to the sham group. Moreover, 8 weeks of LiESWT could significantly reduce urine leakage but increase urine volume and attenuate urgency symptoms, which showed meaningful and persistent improvement at W8, F1, F3, and F6. Furthermore, validated standardized questionnaire scores were significantly improved at W8, F1, F3, and F6 as compared to the baseline (W0). Conclusions: Eight weeks of LiESWT attenuated SUI symptoms upon physical activity, reduced urine leakage, and ameliorated overactive bladder symptoms, which implied that LiESWT significantly improved the quality of life. Our findings suggested that LiESWT could serve as a potentially novel and non-invasive treatment for SUI. Full article
(This article belongs to the Special Issue New Advances in Female Pelvic Floor Dysfunctions Management)
Show Figures

Figure 1

Back to TopTop